<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Rapid and safe recanalization of occluded intracranial arteries in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> (AIS) is challenging </plain></SENT>
<SENT sid="1" pm="."><plain>Newly available self-expanding intracranial atherosclerotic stents (SEIS), which can be deployed rapidly and safely, make <z:hpo ids='HP_0011009'>acute</z:hpo> stenting an option for treating AIS </plain></SENT>
<SENT sid="2" pm="."><plain>We present the feasibility of this technique </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A retrospective analysis evaluated procedural protocols and clinical response to treatment in patients with AIS treated with SEIS </plain></SENT>
<SENT sid="4" pm="."><plain>Descriptive statistics are presented with initial and follow-up National Institutes of Health <z:hpo ids='HP_0001297'>Stroke</z:hpo> Scale and modified Rankin Score </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Nine patients with AIS underwent <z:hpo ids='HP_0011009'>acute</z:hpo> SEIS placement </plain></SENT>
<SENT sid="6" pm="."><plain>There was successful deployment of the Neuroform (n=4) and Wingspan (n=4/5) stents in the M1/M2 (n=5) and M3 (n=1) middle cerebral artery segments, intracranial internal carotid artery (one of 2), and intracranial vertebrobasilar junction (one) </plain></SENT>
<SENT sid="7" pm="."><plain>Mean time of SEIS deployment from AIS <z:hpo ids='HP_0003674'>onset</z:hpo> was 5.1 hours </plain></SENT>
<SENT sid="8" pm="."><plain>Complete (Thrombolysis in <z:hpo ids='HP_0002637'>Cerebral Ischemia</z:hpo>/Thrombolysis in <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">Myocardial Ischemia</z:e> 3) and partial/complete (Thrombolysis in <z:hpo ids='HP_0002637'>Cerebral Ischemia</z:hpo>/Thrombolysis in <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">Myocardial Ischemia</z:e> 2 or 3) recanalization occurred in 67% and 89%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>One <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> (11%) and one <z:hpo ids='HP_0011009'>acute</z:hpo> in-stent <z:mp ids='MP_0005048'>thrombosis</z:mp> (successfully treated with abciximab and balloon angioplasty) occurred </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo>-related mortality occurred in 3 of 9 (33%) patients and survivors had modified Rankin Score &lt; or = 2 </plain></SENT>
<SENT sid="11" pm="."><plain>Follow-up angiography (mean, 8 months; range, 2 to 14 months) in 4 of 9 patients showed no stent restenosis </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: This preliminary experience with SEIS in refractory AIS demonstrated the technical feasibility and high rate of recanalization with <z:hpo ids='HP_0011009'>acute</z:hpo> stenting </plain></SENT>
<SENT sid="13" pm="."><plain>Long-term safety and strategies to limit in-stent <z:mp ids='MP_0005048'>thrombosis</z:mp> and optimize periprocedural management are crucial before initiating future randomized efficacy studies with SEIS in AIS refractory to standard therapy </plain></SENT>
</text></document>